

In the Claims

Please amend Claims 1, 8, 9, 13, 26, 31, 32, 33, 39, 44, 45, 49 and 50. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - iv).

1. (Three times amended) A method for producing a recombinant retroviral particle, said particle comprising an RNA sequence which encodes SDI-1, or a functional analogue or a functional fragment of the RNA sequence which encodes a polypeptide with SDI-1 activity of inhibiting cell proliferation, comprising stably transfecting an isolated producer cell with a retroviral vector comprising a DNA sequence which encodes SDI-1 or a functional analogue or functional fragment which encodes a polypeptide with SDI-1 activity of inhibiting cell proliferation, said producer cell additionally harboring at least one DNA construct coding for proteins required for said retroviral vector to be packaged.
8. (Twice amended) The method of Claim 1, wherein the retroviral vector comprises a 5' LTR region of the structure U3-R-U5; one or more sequences selected from coding and noncoding sequences; and a 3' LTR region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence containing a regulatory element or a promoter, followed by the U5 and R region, characterized in that at least one of the coding sequences is a DNA sequence encoding SDI-1, a functional analogue thereof, or a functional fragment thereof, said sequence being under transcriptional control of said regulatory element or promoter.
9. (Twice amended) The method of Claim 1 wherein the DNA sequence encoding SDI-1, a functional analogue, or a functional fragment thereof, is under transcriptional control of a target cell specific regulatory element or a target cell specific promoter or an X-ray inducible promoter.
13. (Three times amended) An isolated producer cell stably transfected with a retroviral vector comprising a DNA sequence encoding SDI-1, a functional analogue thereof, or a functional fragment thereof, wherein the SDI-1 or functional fragment or functional

analogue thereof inhibits cell proliferation, said producer cell additionally harboring at least one DNA construct coding for the proteins required for said retroviral vector to be packaged.

26. (Three times amended) A method for introducing DNA sequences encoding SDI-1, a functional analogue, or a functional fragment thereof, into human cells in vitro comprising infecting a target cell population with a retroviral particle produced by the producer cell line of Claim 13.
31. (Amended) A method according to Claim 28 wherein the recombinant retroviral particle is administered as an injection, or the recombinant retroviral particle is administered by implantation of a packaging cell line harbouring:
- a) a retroviral vector carrying a DNA sequence encoding SDI-1, a functional analogue, a fragment thereof or an antisense SDI-1 DNA sequence; and
 - b) at least one DNA construct coding for the proteins required for said retroviral vector to be packaged
- into the living animal body, including a human, nearby or at the site of the tumor.
32. (Amended) A method according to Claim 28 wherein the recombinant retroviral particle is administered as an injection, or the recombinant retroviral particle is administered by implantation of an encapsulated packaging cell line comprising encapsulated cells having a core containing packaging cells harbouring:
- a) a retroviral vector carrying a DNA sequence encoding SDI-1, a functional analogue, a fragment thereof or an antisense SDI-1 DNA sequence; and
 - b) at least one DNA construct coding for the proteins required for said retroviral vector to be packaged
- and a porous capsule wall surrounding said core, said porous capsule wall being permeable to the retroviral particles produced by the packaging cells, into the living animal body, including a human, nearby or at the site of the tumor.

33. (Amended) A method for producing a recombinant retroviral particle, said particle comprising an RNA sequence which encodes SDI-1, wherein the SDI-1 inhibits cell proliferation, comprising stably transfecting an isolated producer cell with a retroviral vector comprising a DNA sequence which encodes SDI-1 wherein the SDI-1 inhibits cell proliferation, said producer cell additionally harboring at least one DNA construct coding for proteins required for said retroviral vector to be packaged.
39. (Amended) An isolated producer cell stably transfected with a retroviral vector comprising a DNA sequence encoding SDI-1 wherein the SDI-1 inhibits cell proliferation, said producer cell additionally harboring at least one DNA construct coding for the proteins required for said retroviral vector to be packaged.
44. (Amended) A method for producing a recombinant retroviral particle, said particle comprising an RNA sequence which codes for amino acids 1 to 71 of human SDI-1 and inhibits cell proliferation, comprising stably transfecting an isolated producer cell with a retroviral vector comprising a DNA sequence which encodes SDI-1 wherein the SDI-1 inhibits cell proliferation, said producer cell additionally harboring at least one DNA construct coding for proteins required for said retroviral vector to be packaged.
45. (Amended) An isolated producer cell stably transfected with a retroviral vector comprising a DNA sequence which codes for amino acids 1 to 71 of human SDI-1 and inhibits cell proliferation, said producer cell additionally harboring at least one DNA construct coding for the proteins required for said retroviral vector to be packaged.
49. (Amended) A method for producing a recombinant retroviral particle, said particle comprising an RNA sequence which codes for amino acids 42 to 58 of human SDI-1 and inhibits cell proliferation, comprising stably transfecting an isolated producer cell with a retroviral vector comprising a DNA sequence which encodes SDI-1 wherein the SDI-1 inhibits cell proliferation, said producer cell additionally harboring at least one DNA construct coding for proteins required for said retroviral vector to be packaged.

50. (Amended) An isolated producer cell stably transfected with a retroviral vector comprising a DNA sequence which codes for amino acids 42 to 58 of human SDI-1 and inhibits cell proliferation, said producer cell additionally harboring at least one DNA construct coding for the proteins required for said retroviral vector to be packaged.

Please add the following claims:

54. (New) A recombinant retroviral particle produced by the method of Claim 1.
55. (New) A pharmaceutical composition comprising the retroviral particle of Claim 54 and a pharmaceutically acceptable carrier or diluent.
56. (New) A capsule which encapsulates an isolated producer cell stably transfected with a retroviral vector comprising a DNA sequence encoding SDI-1, said producer cell additionally harboring at least one DNA construct coding for the proteins required for said retroviral vector to be packaged, said capsule comprising a porous capsule wall being permeable to the retroviral particles produced by said producer cell.
57. (New) The capsule of Claim 56 wherein said porous capsule wall comprises a polyelectrolyte complex formed from counter charged polyelectrolytes.
58. (New) A pharmaceutical composition comprising the capsule of Claim 56 and a pharmaceutically acceptable carrier or diluent.
59. (New) A method of treating disorders or diseases responsive to the anti-proliferative activity of SDI-1 in an individual, comprising administering to the individual the capsule of Claim 56.
60. (New) The method according to Claim 59 wherein the disorder or disease is cancer or restenosis.